ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Trial ID or NCT#
NCT01777152
Status
NOT RECRUITING
Purpose
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Investigator(s)
Lauren Maeda, MD
Hematologist,
Lymphoma specialist,
Hematologist-Oncologist
Clinical Associate Professor, Medicine - Oncology
Ranjana Advani
Lymphoma specialist,
Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma
View on ClinicalTrials.gov
